{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T12:34:27Z","timestamp":1770294867699,"version":"3.49.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The acquired <jats:italic>EGFR<\/jats:italic> C797X mutation has been identified as the most notable resistance to osimertinib, and novel secondary mutations of <jats:italic>EGFR<\/jats:italic> L718 and L792 residues have also been demonstrated to confer osimertinib resistance, making the choice of medication after osimertinib treatment a quandary. Dacomitinib has been reported to have potential impact on patients acquiring rare compound mutations after osimertinib resistance; however, little evidence is available to date. In five lung adenocarcinoma patients resistant to later-line osimertinib, recurrent mutations at <jats:italic>EGFR<\/jats:italic> L792 and\/or L718 were identified using targeted next-generation sequencing of tissue or cell-free DNA from plasma or pleural effusion. Dacomitinib was initiated after osimertinib resistance; however, all patients progressed within 2 months. Molecular structural simulation revealed that L792H + T790M and L718Q mutations could interfere with the binding of dacomitinib to EGFR and potentially cause primary drug resistance. Our case series study, to our knowledge, is the first to report the clinical efficacy of dacomitinib in patients harboring rare complex mutations after later-line osimertinib resistance.<\/jats:p>","DOI":"10.3389\/fonc.2021.649843","type":"journal-article","created":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T15:45:07Z","timestamp":1618501507000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Case Report: Dacomitinib May Not Benefit Patients Who Develop Rare Compound Mutations After Later-Line Osimertinib Treatment"],"prefix":"10.3389","volume":"11","author":[{"given":"Hong-Shuai","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang-Jian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer","volume":"376","author":"Mok","year":"2017","journal-title":"New Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2310","article-title":"Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients","volume":"24","author":"Yang","year":"2018","journal-title":"Clin Cancer Res an Off J Am Assoc Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.12.024","article-title":"Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in\u00a0Advanced NSCLC","volume":"12","author":"Chen","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.05.024","article-title":"EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib","volume":"13","author":"Zhang","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.10.026","article-title":"Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro","volume":"126","author":"Nishino","year":"2018","journal-title":"Lung Cancer (Amsterdam Netherlands)."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2016.1139235","article-title":"Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma","volume":"17","author":"Kim","year":"2016","journal-title":"Cancer Biol Ther"},{"key":"B7","doi-asserted-by":"publisher","first-page":"eaan6566","DOI":"10.1126\/scitranslmed.aan6566","article-title":"A method of high-throughput functional evaluation of gene variants of unknown significance in cancer","volume":"9","author":"Kohsaka","year":"2017","journal-title":"Sci Trans Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"viii741","DOI":"10.1093\/annonc\/mdy424.064","article-title":"LBA51 - Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study","volume":"29","author":"Papadimitrakopoulou","year":"2018","journal-title":"Ann Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.2969","article-title":"Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M\u2013Positive Lung Cancer and Acquired Resistance to Osimertinib","volume":"4","author":"Oxnard","year":"2018","journal-title":"JAMA Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br J cancer."},{"key":"B11","doi-asserted-by":"publisher","first-page":"viii740","DOI":"10.1093\/annonc\/mdy424.063","article-title":"LBA50 Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study","volume":"29","author":"Ramalingam","year":"2018","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.07.014","article-title":"Mechanisms of osimertinib resistance and emerging treatment options","volume":"147","author":"Schmid","year":"2020","journal-title":"Lung Cancer (Amsterdam Netherlands)."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.21037\/tcr.2018.09.13","article-title":"EGFR exon 19 deletion switch and development of p.L792Q mutation as a new resistance mechanism to osimertinib: A case report and literature review","volume":"8","author":"Pisapia","year":"2018","journal-title":"Trans Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S194231","article-title":"Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives","volume":"13","author":"Lavacchi","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1158\/1535-7163.MCT-16-0407","article-title":"Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer","volume":"16","author":"Kobayashi","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"B16","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1186\/s12885-019-5915-7","article-title":"Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report","volume":"19","author":"Liu","year":"2019","journal-title":"BMC cancer."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-3819","article-title":"Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance Mutations","volume":"80","author":"Starrett","year":"2020","journal-title":"Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2019.12.002","article-title":"Resolving Resistance to Osimertinib Therapy With Afatinib in an NSCLC Patient With EGFR L718Q Mutation","volume":"21","author":"Yang","year":"2020","journal-title":"Clin Lung Cancer."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2018.138","article-title":"Rare mechanism of acquired resistance to osimertinib in Korean patients with EGFR-mutated non-small cell lung cancer","volume":"51","author":"Lee","year":"2019","journal-title":"Cancer Res Treat"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.07.018","article-title":"Acquired EGFR L718V Mutation and Loss of T790M-Mediated Resistance to Osimertinib in a Patient With NSCLC Who Responded to Afatinib","volume":"14","author":"Fang","year":"2019","journal-title":"J Thoracic Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2018.01.015","article-title":"Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib","volume":"118","author":"Liu","year":"2018","journal-title":"Lung Cancer (Amsterdam Netherlands)."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.08.006","article-title":"Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer","volume":"12","author":"Arulananda","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4994","DOI":"10.18632\/oncotarget.14007","article-title":"The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.649843\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T15:45:10Z","timestamp":1618501510000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.649843\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,15]]},"references-count":23,"alternative-id":["10.3389\/fonc.2021.649843"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.649843","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,15]]},"article-number":"649843"}}